| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CIL41 | CTRPv2 | pan-cancer | AAC | -0.014 | 0.8 |
| mRNA | BRD-A94377914 | CTRPv2 | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | BRD-K09587429 | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | BRD-K50799972 | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | KH-CB19 | CTRPv2 | pan-cancer | AAC | 0.013 | 0.8 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | Obatoclax Mesylate | CTRPv2 | pan-cancer | AAC | 0.0091 | 0.8 |
| mRNA | BRD-K45681478 | CTRPv2 | pan-cancer | AAC | -0.0097 | 0.8 |
| mRNA | TAE684 | CTRPv2 | pan-cancer | AAC | -0.0094 | 0.8 |
| mRNA | PLX4720 | CTRPv2 | pan-cancer | AAC | -0.0093 | 0.8 |